Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Frontier Management
Nanjing, Jiangsu, China
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Frontier Biotechnologies launched Aikening® (albuvirtide), the first long-acting injectable HIV fusion inhibitor, now approved in China with demonstrated safety and efficacy in real-world and Phase III TALENT study. FB2001 (bofutrelvir), targeting Coronavirus Mpro, completed Phase 1 with positive safety results. Multiple programs in early clinical phases targeting antiviral and metabolic diseases.
- Therapeutic areas
- CardiovascularInfectious DiseasesEndocrinologyNeurology
- Modalities
- Long-acting peptideSmall moleculeActive immunotherapy (SAITs)
- Industry
- Biotech
02
Partnerships
AFFiRiS AG (license for AFFITOPE AT04 immunotherapy in Greater China)
Beyond the preview
Go deeper on Frontier Management.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Frontier Management.